Tuesday, February 11, 1:30 p.m. - 2:25 p.m. | Jade
Immuno-oncology has been earning the spotlight over the past year, having been named as Science’s Breakthrough of the Year, and this year’s ASCO will be no exception. Expert panelists will discuss the latest developments in the immuno-oncology space. What will be the talk of ASCO? What does it take to get breakthrough status? Why has this field taken so long to come to fruition? Are immunotherapies the answer to managing cancer over a lifetime?
- Michael G. King, Jr., Senior Analyst, Biotechnology, JMP Securities
- Annalisa Jenkins, MBBS, MRCP, Executive VP & Head of Global Research and Development, Merck KGaA
- Peter G. Traber, MD, President, CEO & CMO, Galectin Therapeutics
- Samuel D. Waksal, PhD, Chairman & CEO, Kadmon Corporation
- Jeffrey S. Weber, MD, PhD, Senior Member, H Lee Moffitt Cancer Center; Director, Donald A. Adam Comprehensive Melanoma Research Center
- Jon Wigginton, MD, Senior Vice President, Clinical Research, MacroGenics
Annalisa Jenkins, MBBS, MRCP
Annalisa Jenkins, MBBS, MRCP, is Executive Vice President, Head of Global Development and Medical for Merck Serono. Dr. Jenkins is also a member of the Pharmaceutical Executive Committee.
Prior to joining Merck Serono, Dr. Jenkins was Senior Vice President, Global Medical Affairs at Bristol-Myers Squibb (BMS). She started with BMS in 1997 as a Cardiovascular Medical Advisor based in the UK. In 2000, she moved to Australia to serve as Executive Medical Director for Australia and New Zealand, subsequently leading the Medical Division across Asia Pacific and Latin America.
In 2002, Dr. Jenkins moved to BMS’s major R&D site in Princeton, New Jersey, to oversee the company’s International Medical Division. After three years in this role, she was appointed Chief Medical Officer (CMO) for Europe, Middle East and Africa, subsequently taking on the position of Senior Vice President and CMO responsible for the Americas and the Development Teams.
Annalisa Jenkins began her career as a Medical Officer with the British Royal Navy, and served with the Minesweeper Squadron during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. She graduated in Medicine from St Bartholomew’s Hospital London and trained in Cardiology with the UK National Health Service.
Michael G. King, Jr.
Mike King is a Managing Director and senior research analyst covering the biotechnology industry. Prior to joining JMP, Mike was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology, and a Managing Director and senior equity analyst at Wedbush Securities.
Beforehand, Mike served as a Managing Director and senior biotechnology analyst both at Merriman Curhan Ford and at Rodman & Renshaw, where, in his initial tenure with the company, he was also the Director of Research. Additionally, Mike has held senior equity research positions at Banc of America Securities, Robertson Stephens, Vector Securities and Dillon Read & Co., covering a wide range of market capitalizations and therapeutic categories. He began his career as a biotechnology specialist in the private client sales divisions of Alex. Brown & Co., Hambrecht & Quist and Kidder, Peabody & Co.
In 2013, Mike ranked first among all stock pickers in the Pharmaceuticals category in the annual “Best on the Street” analyst survey conducted by The Wall Street Journal. Mike holds a BA in finance from The Bernard M. Baruch College of the City University of New York.
Peter G. Traber, MD
Dr. Traber is president emeritus of Baylor College of Medicine, where he was chief executive officer from 2003 to 2008. From 2000 to 2003, he was senior vice president of clinical development and medical affairs and chief medical officer of GlaxoSmithKline plc. Dr. Traber served as chief executive officer of the University of Pennsylvania Health System and was chair of the Department of Internal Medicine and chief of gastroenterology for the University of Pennsylvania School of Medicine. Dr. Traber has also managed a molecular biology research laboratory and published over 100 articles of original research, reviews and book chapters. Dr. Traber received his M.D. from Wayne State School of Medicine, a B.S. in chemical engineering from the University of Michigan, and a certificate in medical leadership from Wharton Business School.
Samuel D. Waksal, PhD
Dr. Waksal is founder and CEO of Kadmon Corporation. Dr. Waksal is the founder and former President and CEO of ImClone Systems (sold to Eli Lilly & Co. in 2008 for $6.5 billion), developer of Erbitux®, one of the top-selling cancer drugs in the world. Dr. Waksal spent the first half of his career in academic medicine. He was a professor of pathology and the director of the Division of Immunotherapy at the Mount Sinai School of Medicine in New York. He also served as visiting investigator at the National Cancer Institute, Immunology Branch, a research associate in the Department of Genetics at Stanford University Medical School, an assistant professor at Tufts University School of Medicine and a senior scientist at the Tufts Cancer Research Center.
Dr. Waksal was a scholar of the Leukemia Society of America, and has been a visiting professor at the Pasteur Institute in France and the Weizmann Institute of Science in Israel. He was a member of the Board of Advisors of Rockefeller University and for many years was the Chairman of the New York State Council for the Humanities.
Dr. Waksal has served as a board member for several public and private companies, including Medicis Pharmaceuticals, Antigenics and ValiGen.
Jeffrey S. Weber, MD, PhD
Jon Wigginton, MD
Dr. Wigginton joined Macrogenics as Senior Vice President, Clinical Research in August, 2013.. Dr. Wigginton was previously the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research and Executive Director, Discovery Medicine-Clinical Oncology at Bristol-Myers from October 2008 to August 2013. While there, he led the early clinical development of the Bristol-Myers’ Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and various immunotherapy combinations. Prior to joining Bristol-Myers, Dr. Wigginton was the Director of Clinical Oncology at Merck Research Laboratories from May 2006 to October 2008, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, Dr. Wigginton held several positions at the National Cancer Institute Center for Cancer Research (NCI-CCR), including Head of the Investigational Biologics Section, Pediatric Oncology Branch. He also is a Past-President and a current member of the Executive Council of the Society for Immunotherapy of Cancer (SITC). Dr. Wigginton received his M.D. and B.S. in Biology from the University of Michigan.